2026-01-27 - Analysis Report
## Invesco (IVZ) Overview
Invesco is an American investment management company.

## Performance Comparison

| Ticker | Cumulative Return |
|--------|--------------------|
| IVZ    | 84.34%             |
| VOO    | 127.58%            |

The cumulative return of IVZ is 33.46% lower than the S&P 500 (VOO).

## Alpha, Beta Analysis

| Period | CAGR | MDD | Alpha | Beta | Cap(B) |
|--------|-----|----|-------|------|--------|
| 2016-2018 | -40.0% | 36.4% | -49.0% | 1.4 | 7.5B  |
| 2017-2019 | -23.0% | 36.4% | -49.0% | 1.2 | 8.0B  |
| 2018-2020 | -23.0% | 57.4% | -47.0% | 1.5 | 7.8B  |
| 2019-2021 | 59.0% | 57.4% | -6.0% | 1.6 | 10.3B |
| 2020-2022 | 27.0% | 57.4% | 23.0% | 1.6 | 8.0B  |
| 2021-2023 | -7.0% | 40.7% | -25.0% | 1.5 | 8.0B  |
| 2022-2024 | -12.0% | 35.5% | -42.0% | 1.4 | 7.8B  |
| 2023-2025 | 66.0% | 34.6% | -10.0% | 1.5 | 11.7B |

## Stock Price Fluctuation

| Period | Close |
|--------|-------|
| 5-day SMA | $28.67 |
| 20-day SMA | $28.09 |
| 60-day SMA | $25.86 |

IVZ's recent stock price has been fluctuating around $28.63, with the 5-day SMA at $28.67 and the 20-day SMA at $28.09.

## Technical Indicators

| Indicator | Value |
|-----------|-------|
| RSI       | 53.20 |
| PPO       | -0.32 |
| MRI       | 0.70 |

IVZ's RSI is at 53.20, indicating neutral sentiment. The PPO is -0.32, suggesting a downward trend. The Market Risk Indicator (MRI) is 0.70, indicating a medium-risk investment opportunity.

## Recent News & Significant Events

* How The New Price Target Is Quietly Shaping Invescoâ€™s (IVZ) Evolving Story - Yahoo Finance UK
* Assessing Invesco (IVZ) Valuation After RBC Upgrade And Upbeat Earnings Outlook - simplywall.st
* Invesco Earnings: What To Look For From IVZ - Finviz
* Invesco (IVZ) Stock Trades Up, Here Is Why - The Globe and Mail
* Invesco: Asset Manager Hits Ceiling Of Fair Value - Seeking Alpha
* Higher AUM on Upbeat Markets to Drive Invesco's Q4 Earnings - Nasdaq

## Analyst Opinions
```text
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.33 (~Buy)
- Opinions: 11
- Target Price (avg/high/low): 30.39 / 35.00 / 24.00
```

## Recent Earnings Analysis

| Date | EPS | Revenue |
|------|-----|---------|
| 2025-11-04 | 0.67 | 1.64B$  |
| 2025-08-01 | -0.03 | 1.52B$  |
| 2025-04-28 | 0.38 | 1.53B$  |
| 2024-10-29 | 0.12 | 1.52B$  |
| 2025-11-04 | 0.12 | 1.52B$  |

## Revenue and Profitability

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $1.64B  | 34.17%        |
| 2025-06-30 | $1.52B  | 33.28%        |
| 2025-03-31 | $1.53B  | 36.33%        |
| 2024-12-31 | $1.59B  | 37.83%        |
| 2024-09-30 | $1.52B  | 25.76%        |

## Capital and Profitability

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $14.01B | 2.47% |
| 2025-06-30 | $13.87B | 1.47% |
| 2025-03-31 | $14.70B | 1.57% |
| 2024-12-31 | $14.56B | 1.84% |
| 2024-09-30 | $14.75B | 0.77% |

## Comprehensive Analysis (Summary of previous items)
IVZ has a cumulative return of 84.34%, which is 43.24% lower than the S&P 500. The RSI is at 53.20, indicating neutral sentiment, while the PPO is -0.32, suggesting a downward trend. The stock price has been fluctuating around $28.63, with the 5-day SMA at $28.67 and the 20-day SMA at $28.09. Analysts recommend buying the stock, with a target price range of $24.00 to $35.00.

The company has been experiencing fluctuating quarterly earnings, with EPS ranging from -0.03 to 0.67. Revenue has been increasing, with quarter-end figures ranging from $1.52B to $1.64B. The profit margin has also been fluctuating, ranging from 25.76% to 37.83%.

Overall, IVZ presents a mixed investment opportunity, with both positive and negative indicators. The company's recent news and significant events suggest a potential for growth, while the technical indicators and quarterly earnings indicate mixed sentiment. As with any investment, caution and thorough research are advised before making any decisions.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.